The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The evolving role of JAK inhibitors in myelofibrosis
Gonzalo Carreño Gómez-Tarragona, MD, PhD, 12 de Octubre University Hospital, Madrid, Spain, discusses the evolving role of JAK inhibitors in myelofibrosis, highlighting the benefits of momelotinib for patients with anemia and the potential for emerging combination strategies to further improve long-term disease outcomes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Currently we have three approved JAK inhibitors, ruxolitinib, fedratinib and momelotinib. Ruxolitinib was the first drug of its class. Really, it changed the landscape of how we treat the patients. But one of the adverse events, it caused cytopenias or low platelets and anemia. Fedratinib has a similar profile as ruxolitinib and it’s mainly used as second line and then we have momelotinib which not only inhibits JAK but also inhibits ACVR1...
Currently we have three approved JAK inhibitors, ruxolitinib, fedratinib and momelotinib. Ruxolitinib was the first drug of its class. Really, it changed the landscape of how we treat the patients. But one of the adverse events, it caused cytopenias or low platelets and anemia. Fedratinib has a similar profile as ruxolitinib and it’s mainly used as second line and then we have momelotinib which not only inhibits JAK but also inhibits ACVR1. So that makes patients have responses in anemia. So it’s a really good drug for cytopenic patients with myelofibrosis. And the results are quite good. It might take a long time. I mean, we must be patient in order to achieve those responses, but really it has changed the landscape of treatment. And about the unmet needs that we may have in myelofibrosis, I think that we’re seeing in this, indeed, that we’re moving towards combination therapies that might modify the natural history of the disease, which is our main and final goal.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
